Scientists recently demonstrated that biphasic vesicles can deliver large-molecule or macromolecule drugs into the skin. Success with biphasic vesicles offers the potential for needle-free administration of many pharmaceuticals that could previously only be administered by injection.
Eli Lilly plans to cut hundreds of workers from its U.S. sales force as the drugmaker prepares to deal with the loss of patent protection for two more top-selling drugs. Lilly spokesman Scott MacGregor declined to disclose the specific number of cuts, but did say it totals less than 1,000 full-time employees.
Predicting the side effects of drugs remains one of the industry’s greatest challenges, with a large percentage of new drugs failing in clinical studies due to cardiac toxicity. The overall success rate from Phase 1 studies is only 11%, with 30% of these failing for safety reasons.
Available in both immersion probe and flow through styles, these compact systems are ideal for cooling exothermic reactions, freeze point determinations, freeze drying, impact testing, lyophilization, and vapor and solvent trapping.
Biosearch Technologies Inc. has announced the acquisition of exclusive worldwide rights to continuing Stellaris RNA FISH-based inventions from the University of Medicine and Dentistry of New Jersey.
SPOT Imaging Solutions has released the ultra-sensitive SPOT Pursuit USB digital camera. The SPOT Pursuit camera combines high image quality with excellent temporal resolution for rapid time-lapse recordings, allowing researchers to document live cells and photobleaching fluorescence specimens with ease.
Researchers have discovered a new therapy for the fragile X chromosome syndrome (FXS). This therapy proposes the modulation of the cerebral endocannabinoid system in order to ameliorate the symptoms of the disease. Using Rimonabant normalizes cognitive alterations, sensitivity to pain, and epileptic crises.
Boston Therapeutics Inc. has requested an Investigational New Drug application meeting with the U.S. Food and Drug Administration. The application will support a proposed indication of PAZ320 to reduce the elevation of post-meal blood sugar for treatment of patients with type 2 diabetes.
Generic drugmaker Actavis Inc. and brand-name drugmaker Valeant Pharmaceuticals International Inc. said they have reached agreements allowing Actavis to sell copycat versions of two medicines for skin conditions years before their patents expire.
Merck & Co. said that the Food and Drug Administration is reviewing its application to sell a pill form of its drug for preventing dangerous fungal infections in high-risk patients. Noxafil, known chemically as posaconazole, is already sold in a liquid form.
Pfizer Inc. said that its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration. The breakthrough designation is meant to speed up development and review of treatments that are seen as big advances over existing therapies.
Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte cell products to the biopharma and academic research markets.
Cresset announced the release of a new version of its computational chemistry workbench forgeV10. This release is the first major update following the launch of forgeV10 in 2012.
MKS Instruments Inc. announced the introduction of the I-Series of mass flow controllers designed for use in harsh environments where resistance to liquid or dust ingress (IP66 rated) is essential.
Eli Lilly and Company unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. this week. The data reflect Lilly's diverse oncology pipeline via molecules that target several pathways...